Financial results for the period ended September 30, 2026
As filed · Amrutanjan Health Care Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
EarningsMajormateriality 75 out of 100
What happened
FactFinancial results for the period ended September 30, 2026. the Limited Review Report issued by M/s. B S R & Co. LLP, Statutory Auditors of the Company is enclosed. Limited Review Report.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Demand
RevisedEarlierQ1 FY27
As investors know, 65% of company revenue is contributed from the Pain Management category.
NowQ1 FY27
The volume growth of the category in Q1 was -3.4% over same period last year.
Change
FactTarget revision
Implication
CapitSignal interpretationThe stated figure moved -94.77%.confidence 60%
Watch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- We are projecting annual revenues of 15 cr for these brands this year. (management committed by FY27)
- Projections for the year targeted at 10 cr. (management committed by FY27)
Evidence
- Amrutanjan Health Care Limited has informed the Exchange that Board of Directors at its meeting held on November 03, 2026, declared Interim Dividend of Re. 1 per equity share.(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +2 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%